Evolving changes in disease biomarkers and risk of early progression in smoldering multiple myeloma

@inproceedings{Ravi2016EvolvingCI,
  title={Evolving changes in disease biomarkers and risk of early progression in smoldering multiple myeloma},
  author={Praful Ravi and Shaji K Kumar and Jeremy T Larsen and Wilson I Gonsalves and Francis K Buadi and Martha Q. Lacy and Ronald S Go and Angela Dispenzieri and Prashant Kapoor and John A. Lust and David Dingli and Yi Lin and Stephen Russell and Nelson Leung and Morie A Gertz and Robert A Kyle and P Leif Bergsagel and S Vincent Rajkumar},
  booktitle={Blood cancer journal},
  year={2016}
}
We studied 190 patients with smoldering multiple myeloma (SMM) at our institution between 1973 and 2014. Evolving change in monoclonal protein level (eMP) was defined as ⩾10% increase in serum monoclonal protein (M) and/or immunoglobulin (Ig) (M/Ig) within the first 6 months of diagnosis (only if M-protein ⩾3 g/dl) and/or ⩾25% increase in M/Ig within the first 12 months, with a minimum required increase of 0.5 g/dl in M-protein and/or 500 mg/dl in Ig. Evolving change in hemoglobin (eHb) was… CONTINUE READING
Recent Discussions
This paper has been referenced on Twitter 30 times over the past 90 days. VIEW TWEETS

From This Paper

Figures, tables, and topics from this paper.

References

Publications referenced by this paper.
Showing 1-10 of 21 references

Positron emission tomographycomputed tomography in the diagnostic evaluation of smoldering multiple myeloma : identi fi cation of patients needing therapy

  • MV Mateos, MT Hernandez, P Giraldo, J delaRubia, F deArriba, L LopezCorral
  • Blood Cancer J
  • 2015

Similar Papers

Loading similar papers…